 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > Biomarkers Predict In-Hospital Major Adverse Cardiac Events in COVID-19 Patients : |
(St George London) (University of Siena. Department of Medical Biotechnologies) (University of Siena. Department of Medical Biotechnologies) (Luton and Dunstable University Hospital) (University of Modena and Reggio Emilia (Itàlia)) (Guglielmo da Saliceto Hospital (Itàlia)) (University of Salerno. Department of Medicine, Surgery and Dentistry) (University of Salerno. Department of Medicine, Surgery and Dentistry) (S. Elia Hospital (Itàlia). Department of Internal Medicine) (Karolinska Institutet (Estocolm, Suècia). Department of Molecular Medicine and Surgery) (University of Naples "Federico II". Department of Advanced Biomedical Sciences) (Hospital Universitari Vall d'Hebron. Institut de Recerca) (University Clinical Centre of Kosova- Clinic of Cardiology) (Umeå University. Department of Public Health and Clinical Medicine) (Siena University Hospital (Siena, Itàlia)) (University of Prishtina "Hasan Prishtina". Medical Faculty) (University of Siena. Department of Medical Biotechnologies)| Data: | 2021 |
| Resum: | Background: The COVID-19 pandemic carries a high burden of morbidity and mortality worldwide. We aimed to identify possible predictors of in-hospital major cardiovascular (CV) events in COVID-19. Methods: We retrospectively included patients hospitalized for COVID-19 from 10 centers. Clinical, biochemical, electrocardiographic, and imaging data at admission and medications were collected. Primary endpoint was a composite of in-hospital CV death, acute heart failure (AHF), acute myocarditis, arrhythmias, acute coronary syndromes (ACS), cardiocirculatory arrest, and pulmonary embolism (PE). Results: Of the 748 patients included, 141(19%) reached the set endpoint: 49 (7%) CV death, 15 (2%) acute myocarditis, 32 (4%) sustained-supraventricular or ventricular arrhythmias, 14 (2%) cardiocirculatory arrest, 8 (1%) ACS, 41 (5%) AHF, and 39 (5%) PE. Patients with CV events had higher age, body temperature, creatinine, high-sensitivity troponin, white blood cells, and platelet counts at admission and were more likely to have systemic hypertension, renal failure (creatinine ≥ 1. 25 mg/dL), chronic obstructive pulmonary disease, atrial fibrillation, and cardiomyopathy. On univariate and multivariate analysis, troponin and renal failure were associated with the composite endpoint. Kaplan-Meier analysis showed a clear divergence of in-hospital composite event-free survival stratified according to median troponin value and the presence of renal failure (Log rank p < 0. 001). Conclusions: Our findings, derived from a multicenter data collection study, suggest the routine use of biomarkers, such as cardiac troponin and serum creatinine, for in-hospital prediction of CV events in patients with COVID-19. |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Matèria: | COVID-19 ; SARS-CoV2 ; Biomarkers ; Troponin ; Creatinine ; Prognosis |
| Publicat a: | Journal of clinical medicine, Vol. 10 (december 2021) , ISSN 2077-0383 |
